Iron Deficiency Anemia Therapy Market Size Projected To Reach 6.51 Billion By 2034 With A Cagr Of 7.8%

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Projected Growth of the Iron Deficiency Anemia Therapy Market?
The market size for treatment of iron deficiency anemia has seen robust growth recently, and it is projected to expand from $4.46 billion in 2024 to $4.82 billion in 2025. This indicates a compound annual growth rate (CAGR) of 8.1%. The growth seen in the past is due to factors such as increased research and development as well as the introduction of innovative drugs. Other contributors would be the progress in iron supplements, the growing incidence of iron deficiency anemia, heightened concentration on social healthcare, and enhancements in treatment alternatives.

In the forthcoming years, the market size of iron deficiency anemia therapy is projected to experience substantial growth, anticipated to reach $6.51 billion by 2029 with a compound annual growth rate (CAGR) of 7.8%. Growth factors contributing to this expansion within the prediction period include increased marketing activities, heightened awareness campaigns, the proliferation of specialized medicine developments, dietary shifts and nutritional deficiencies, and the broadening variety of iron-based treatment options. Additionally, the escalating prevalence of maternal iron deficiency also adds to the market growth. Key market trends within this period are expected to embrace iron-focused nanotechnology, wearable health technology, intelligent iron supplements, blood iron biometric devices, and nanorobots for iron delivery.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24265&type=smp

What Are the Different Iron Deficiency Anemia Therapy Market Segments?
The iron deficiency anemia therapy market covered in this report is segmented -

1) By Product Type: Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumerate, Ferric Hydroxide
2) By Therapy Type: Parenteral Iron Therapy, Oral Iron Therapy, Red Blood Cell Transfusion, Other Therapy Types
3) By Therapy Areas: Inflammatory Bowel Diseases, Renal Diseases, Obstetrics and Gynecology, Congestive Heart Failure, Oncology
4) By Distribution channel: Hospital Pharmacy, Drug Stores And Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Speciality Clinics, Home Care Setting, Other End Users

Subsegments:
1) By Ferrous Sulphate: Oral Ferrous Sulphate Tablets, Oral Liquid Ferrous Sulphate, Intravenous Ferrous Sulphate, Extended Or Delayed Release Formulations
2) By Ferrous Gluconate: Oral Tablets, Chewable Tablets, Liquid Solutions, Pediatric Formulations
3) By Ferrous Fumarate: Oral Tablets Or Capsules, Prenatal Supplements, Multivitamin with Iron Formulations, Pediatric Drops Or Syrups
4) By Ferric Hydroxide: Intravenous Iron Therapy, Ferric Hydroxide Polymaltose Complex, Dialysis-Specific Iron Therapy, Hospital-Based Injectable Formulations

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24265&type=smp

What Are the Primary Drivers Shaping the Iron Deficiency Anemia Therapy Market?
The escalating rates of chronic diseases are anticipated to stimulate the expansion of the iron deficiency anemia therapy market. Chronic diseases are long-term health conditions that generally persist for at least a year. The surge in these conditions is largely due to the mounting prevalence of unhealthy lifestyles, encompassing poor diet, sedentary habits, and smoking. These behaviors are linked to conditions like obesity, diabetes, and cardiovascular disease, which can lead to prolonged health complications. Chronic diseases can amplify the demand for iron deficiency anemia therapy as they can obstruct the body's capability to adequately absorb iron, increasing the likelihood of iron deficiency and necessitating iron supplementation or treatment. For example, the UK's National Health Service reported that in June 2024, the number of people registered with a GP who were diagnosed with non-diabetic hyperglycemia, or pre-diabetes, in 2023 was 3,615,330, marking an 18% rise from 3,065,825 cases in 2022. Thus, the growing incidence of chronic diseases is fuelling the growth of the iron deficiency anemia therapy market.

Which Companies Are Leading in the Iron Deficiency Anemia Therapy Market?
Major companies operating in the iron deficiency anemia therapy market are Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Akebia Therapeutics Inc., Otsuka Pharmaceutical Co Ltd, AdvaCare Pharma USA LLC, Apotex Inc., Ironic Biotech AB, KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Shield Therapeutics plc.

What Iron Deficiency Anemia Therapy Market Trends Are Gaining Traction Across Different Segments?
Leading corporations in the iron deficiency anemia therapy market are prioritizing the development of improved treatment methods, like injectable versions, to amplify treatment efficacy and accessibility. The term "new injectable formulation" pertains to a recently made or modified drug administered through injection. For instance, Emcure Pharmaceuticals Ltd., a pharmaceutical firm based in India, introduced Orofer FCM 750 in May 2023. This is a ferric carboxymaltose (FCM) formulation intended to cure iron deficiency and iron deficiency anemia (IDA). The treatment boasts enhanced patient adherence due to its less frequency of administration as compared to oral supplements. The main objective is to efficiently manage iron deficiency anemia, especially in individuals unable to tolerate oral iron supplements. Orofer FCM 750 is a 750 mg/15 ml ferric carboxymaltose injectable solution approved by India's DCGI to treat iron deficiency anemia (IDA) in patients who show no response to oral iron, notably pregnant women with hemoglobin

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.